Hansa Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results
https://www.hansabiopharma.com/media/press-releases/2025/hansa-biopharma-reports-fourth-quarter-and-full-year-2024-financial-results/
https://www.hansabiopharma.com/media/press-releases/2025/hansa-biopharma-reports-fourth-quarter-and-full-year-2024-financial-results/
Year-end Report
https://www.hansabiopharma.com/files/Main/1219/4101367/20250206-hansa-biopharma-q4-and-fy-2024-report.pdf
https://www.hansabiopharma.com/files/Main/1219/4101367/20250206-hansa-biopharma-q4-and-fy-2024-report.pdf
Hansa Biopharma: Ends 2024 on a softer note
Research Note 2025-02-06 08:15
After a period of steady increase in both European Idefirix sales and patient usage, Hansa records a softer Q4, with sales limited to SEK 25.6m. Hansa does not expect to record any material provisions related to retroactive discounts after 2024. Hansa enters 2025 with a more significant number of centres using Idefirix and improved support from European guidelines.
https://www.redeye.se/research/1072967/hansa-biopharma-ends-2024-on-a-softer-note
Research Note 2025-02-06 08:15
After a period of steady increase in both European Idefirix sales and patient usage, Hansa records a softer Q4, with sales limited to SEK 25.6m. Hansa does not expect to record any material provisions related to retroactive discounts after 2024. Hansa enters 2025 with a more significant number of centres using Idefirix and improved support from European guidelines.
https://www.redeye.se/research/1072967/hansa-biopharma-ends-2024-on-a-softer-note
